CLIMB BIO INC. - COMM
3.5200
07-November-24 15:59:59
15 minutes delayed
Stocks
-0.1300
-3.56%
Today's range
3.4900 - 3.7850
ISIN
N/A
Source
NASDAQ
-
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
15 Aug 2022 06:10:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Provides ETX-810 Program Update
02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire
-
18 Jul 2022 07:00:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022
07 Jul 2022 07:00:00 By Nasdaq GlobeNewswire
-
27 Jun 2022 16:01:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
16 May 2022 06:10:00 By Nasdaq GlobeNewswire
-
Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs
25 Apr 2022 07:00:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs
05 Apr 2022 07:00:01 By Nasdaq GlobeNewswire
-
Eliem Therapeutics to Present at Stifel’s 2022 CNS Days
21 Mar 2022 07:00:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights
07 Mar 2022 16:10:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 Feb 2022 07:00:00 By Nasdaq GlobeNewswire
-
07 Feb 2022 07:00:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones
18 Jan 2022 07:00:01 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
08 Nov 2021 16:01:00 By Nasdaq GlobeNewswire
-
Eliem Therapeutics to Participate at Four Upcoming Investor Conferences
04 Nov 2021 07:00:01 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Reports Second Quarter Financial Results
13 Sep 2021 16:10:00 By Nasdaq GlobeNewswire
-
12 Aug 2021 21:06:11 By Nasdaq GlobeNewswire
-
Eliem Therapeutics Announces Pricing of Initial Public Offering
09 Aug 2021 22:33:09 By Nasdaq GlobeNewswire